NVILE forecast ·
Amgen (AMGN) Stock Forecast: Next 30 Days
AMGN has an 80% calibrated range of $409.72 to $535.46 over the next 30 days from its $465.45 close. Today's earnings release (2026-11-03) is the primary swing factor: recent results average a 5.2% single-day move, options imply a ~4.3% move, and there is a 10% chance of a >10% single-day move. Odds of a >10% move across 30 days are 20% upward and 15% downward. Expected value of $468.39 represents the neutral distribution midpoint, not a directional forecast.
Price now
$465.45
Nov 2, 2026
In 30 days
$468.39
NVILE forecast
Expected move
+0.6%
Range
$409.72–$535.46
What to do
- Size post-earnings exposures using the $409.72 to $535.46 calibrated 80% range rather than spot directional assumptions.High distribution spread reflects substantial multi-week variance regardless of the single-session earnings reaction.
- Avoid establishing unhedged long positions ahead of the 2026-11-03 earnings print.[4]Options price a 4.25% immediate swing and Wall Street's $397.32 mean target implies severe valuation risk upon guidance misses.
Why
- AMGN's calibrated 80% probability distribution spans $409.72 to $535.46 across the next 30 days, with a 20% chance of rising over 10% and a 15% chance of falling over 10%.
- Earnings scheduled for 2026-11-03 represent the primary volatility catalyst, with options pricing an implied move of approximately 4.25% against a historical average move of 5.20%.[4]
- Wall Street consensus reflects skepticism; the 12-month mean target of $397.32 implies a 14.6% downside from the current $465.45 level.[4]
- Q3 earnings execution is the primary driver following a strong prior quarter where reported EPS of $5.64 beat consensus by 12.5%.[4]
- Elevated short-sale volume signals heightened market-maker hedging and tactical hedging activity ahead of binary earnings results.[1]
What could go wrong
- State-level drug price control legislation referencing the IRA and 340B Program presents ongoing structural regulatory headwinds.[3],[5]
- Six insider sales totaling $4.11M with zero insider open-market purchases over the prior 90 days signal caution at senior management levels.[2]
- A negative earnings surprise risks triggering a rapid mean reversion toward the consensus target of $397.32 or the lower 80% bound of $409.72.[4]
How it connects
- Derek Millerserves as SVP Human Resources and sold 3,890 shares inAmgen Inc.[2]
- Rachna Khoslaserves as SVP Business Development and sold 2,000 shares inAmgen Inc.[2]
- Nancy A. Grygielserves as SVP & CCO and sold 1,970 shares inAmgen Inc.[2]
- Financial Industry Regulatory Authority (FINRA)reports daily short-sale volume under Reg SHO forAmgen Inc.[1]
- Securities and Exchange Commission (SEC)receives statutory 10-K, 10-Q, and Form 4 filings fromAmgen Inc.[3],[2],[5]
- Amgen Inc.addressed July MFN Letter matters via agreement withUS Administration[3],[5]
- Amgen Inc.faces pricing controls referencingInflation Reduction Act (IRA)[3],[5]
- Amgen Inc.monitors state-level restrictions and regulations governing340B Drug Pricing Program[3],[5]
NVILE's track record on this page
| Made | Forecast | Actual | Result |
|---|---|---|---|
| Nov 3, 2026 | $468.39 | Due Dec 3, 2026 | Pending |
Every published call is scored when it comes due. See all results →
Sources
Questions
What is the Amgen forecast for the next 30 days?
NVILE's models put Amgen at about $468.39 in 30 days, +0.6% from $465.45. AMGN has an 80% calibrated range of $409.72 to $535.46 over the next 30 days from its $465.45 close. Today's earnings release (2026-11-03) is the primary swing factor: recent results average a 5.2% single-day move, options imply a ~4.3% move, and there is a 10% chance of a >10% single-day move. Odds of a >10% move across 30 days are 20% upward and 15% downward. Expected value of $468.39 represents the neutral distribution midpoint, not a directional forecast.
What price range does NVILE expect for Amgen?
The forecast range is $409.72 to $535.46 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.
What could change the Amgen outlook?
State-level drug price control legislation referencing the IRA and 340B Program presents ongoing structural regulatory headwinds. Six insider sales totaling $4.11M with zero insider open-market purchases over the prior 90 days signal caution at senior management levels. A negative earnings surprise risks triggering a rapid mean reversion toward the consensus target of $397.32 or the lower 80% bound of $409.72.
What should investors watch or do about Amgen?
Size post-earnings exposures using the $409.72 to $535.46 calibrated 80% range rather than spot directional assumptions. Avoid establishing unhedged long positions ahead of the 2026-11-03 earnings print.
How accurate are NVILE forecasts?
Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.
This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.